Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

2024 Updates in the Management of DLBCL, FL, and HL

UNC Lineberger Comprehensive Cancer Center

A. Beaven

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Therapeutic Advances in T-Cell Lymphoma in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Barta

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

ASH 2024 Insights: Real-World Outcomes With Evolving Management of C…

2024 ASH Annual Meeting Insights Hub

R. Bansal

Infectious Complications in Pts Receiving CD19 vs. BCMA Targeted CAR…

Muhammad Abid

Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do a…

Indy Hematology Review

T. Phillips

Epcoritamab in NHL - Incidence and Management of CRS

GRACE

T. Phillips

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

SOHO Brazil 2024

A. Zelenetz

Current Overview of Biscpecific Antibodies in Hematologic Malignanci…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

B. Uncu Ulu

ASCO® 2024 Insights: "TRANSFORM Study - 3-Year Follow-Up Comparing L…

2024 ASCO® Annual Meeting Insights Hub

M. Kamdar

Update on Cellular Therapy in Lymphoma

Total Health

B. Randolph

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

The Evolving Role for Bispecific Antibodies in B-Cell Lymphoma

UChicago Medicine

T. Mccabe